Metformina Stadafarma

Metformin Hydrochloride, the active ingredient in Metformina Stadafarma, is a biguanide presented as a tablet for oral use. It lowers elevated blood glucose in adults with type 2 diabetes mellitus. GNH USA supplies Metformina Stadafarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina Stadafarma is a biguanide that acts on glucose metabolism in type 2 diabetes and related conditions.

- Type 2 diabetes mellitus: improves glycaemic control by reducing hepatic glucose output and enhancing peripheral insulin sensitivity. - Impaired glucose tolerance: delays progression to overt diabetes when used as part of lifestyle intervention. - Polycystic ovary syndrome: reduces insulin resistance and may help restore ovulatory cycles.

Metformina Stadafarma is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, and diarrhoea. - Metallic taste in the mouth. - Decreased appetite. - Mild headache. - Weight loss: modest reduction in body weight.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Severe hypoglycaemia: usually when combined with insulin or sulfonylureas. - Hepatic dysfunction: elevated liver enzymes. - Allergic reactions: rash, pruritus, or angio‑edema. - Vitamin B12 deficiency with long‑term use.

Metformina Stadafarma requires careful patient assessment and monitoring.

- Renal function: assess creatinine clearance before initiation and periodically thereafter. - Lactic acidosis risk: avoid in patients with acute or chronic metabolic acidosis. - Alcohol consumption: limit intake to reduce acidosis risk. - Concomitant hypoglycaemic agents: monitor for additive glucose‑lowering effects. - Pregnancy and breastfeeding: use only if potential benefit justifies potential risk. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Metformina Stadafarma can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate renal impairment and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Alcohol: enhances risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: increased risk of hypoglycaemia. - Beta‑blockers: may mask hypoglycaemic symptoms. - Thiazide diuretics: possible attenuation of glucose‑lowering effect.